# Left Atrial Strain Correlation with Functional Capacity and Additional Prognostic Value of Speckle Tracking in Cardiac Amyloidosis: A Prospective, Single-Center Study

**Authors:** Maria Concetta Pastore, Marta Focardi, Federica Marrese, Elisa Giacomin, Gian Luca Ragazzoni, Francesca Susini, Alessandro Gozzetti, Giulia Elena Mandoli, Luna Cavigli, Elena Placuzzi, Laura Spaccaterra, Sara Rosi, Lorenzo Tanzi, Flavio D’Ascenzi, Serafina Valente, Matteo Cameli

PMC · DOI: 10.3390/jcm15041337 · 2026-02-08

## TL;DR

This study shows that left atrial strain measured by speckle tracking can predict disease severity and outcomes in cardiac amyloidosis patients.

## Contribution

The study demonstrates the additional prognostic value of left atrial strain in cardiac amyloidosis.

## Key findings

- Global peak atrial longitudinal strain (PALS) correlates with NTproBNP and 6MWT in cardiac amyloidosis.
- PALS and GLS outperformed NTproBNP in predicting adverse outcomes.
- PALS < 13.5% and GLS > −12% were strong predictors of the combined endpoint.

## Abstract

Background: Cardiac amyloidosis (CA) is mainly characterized by diastolic dysfunction, with gradually worsening functional capacity and poor prognosis. Left atrial (LA) strain by speckle tracking echocardiography (STE) is an index of diastolic function and heart failure (HF) symptoms. The aim of this study was to evaluate the relationship of LA strain with functional capacity in CA and the potential prognostic value of speckle tracking variables. Methods: In this single-center study, we prospectively enrolled consecutive outpatients with CA (n = 75). Clinical, echocardiographic evaluation, six-minute-walking-test (6MWT) and Kansas City Cardiomyopathy Questionnaire (KCCQ) were performed on the same day. The primary endpoint was the correlation between global peak atrial longitudinal strain (PALS) and NTproBNP, 6MWT score, and KCCQ. The secondary endpoint was a combination of all-cause or cardiovascular death and HF hospitalization. Results: Overall, 48 ATTR and 27 AL patients (74 ± 11 years, 84% male) were enrolled. Global PALS showed a significant direct correlation with N-terminal-pro-brain natriuretic peptide (NTproBNP, p = 0.3, p = 0.017) and 6MWT (p = 0.4, R2 = 0.2, p = 0.004), but no significant correlation with KCCQ (p = −0.13, p = 0.3). GLS showed a significant direct correlation with NTproBNP (p = 0.3, p = 0.017) but not with 6MWT and/or KCCQ. Over a mean follow up of 12 ± 3 months, 42 patients reached the combined endpoint. With ROC curves, both global PALS < 13.5% and GLS > −12% provided a good prediction of the combined endpoint (AUC = 0.72 [0.6–0.82] and 0.73 [0.63–0.83], respectively, p < 0.0001), higher than NTproBNP and other echocardiographic parameters. Conclusions: Global PALS is associated with congestion and functional capacity in CA, suggesting its role as a more objective marker of disease severity in CA. Speckle tracking parameters may be used to enhance prognostic stratification in CA.

## Linked entities

- **Diseases:** heart failure (MONDO:0005252)

## Full-text entities

- **Genes:** TTR (transthyretin) [NCBI Gene 7276] {aka AMYLD1, ATTR, CTS, CTS1, HEL111, HsT2651}
- **Diseases:** ATTR amyloidosis (MESH:C567782), HFpEF (MESH:D054144), impaired LA function (MESH:D059446), HCMs (MESH:D000092183), atrial restrictive dysfunction (MESH:D002313), hypertrophic cardiomyopathy (MESH:D002312), Cardiomyopathy (MESH:D009202), fatigue (MESH:D005221), systolic dysfunction (MESH:D006331), amyloid (MESH:C000718787), coronary artery disease (MESH:D003324), AL CA (MESH:D000075363), AL (MESH:D000686), LV damage (MESH:D018487), HF (MESH:D006333), Anderson-Fabry cardiomyopathy (MESH:D000795), diastolic (MESH:D006337), AL (MESH:D009101), dyspnea (MESH:D004417), cardiovascular (MESH:D002318), congestion (MESH:D002311), valvular heart disease (MESH:D006349), heart or lung disease (MESH:D008171), hypertrophy (MESH:D006984), deaths (MESH:D003643), LV hypertrophy (MESH:D017379), injury to (MESH:D014947)
- **Chemicals:** tafamidis (MESH:C547076), oxygen (MESH:D010100), N-terminal pro brain natriuretic peptide (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941903/full.md

---
Source: https://tomesphere.com/paper/PMC12941903